Article

Molecular signatures database (MSigDB) 3.0.

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Bioinformatics (Impact Factor: 4.62). 06/2011; 27(12):1739-40. DOI: 10.1093/bioinformatics/btr260
Source: PubMed

ABSTRACT Well-annotated gene sets representing the universe of the biological processes are critical for meaningful and insightful interpretation of large-scale genomic data. The Molecular Signatures Database (MSigDB) is one of the most widely used repositories of such sets.
We report the availability of a new version of the database, MSigDB 3.0, with over 6700 gene sets, a complete revision of the collection of canonical pathways and experimental signatures from publications, enhanced annotations and upgrades to the web site.
MSigDB is freely available for non-commercial use at http://www.broadinstitute.org/msigdb.

0 Followers
 · 
225 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: microRNAs (miRNAs) are short non-coding RNAs that play important roles in post-transcriptional regulations as well as other important biological processes. Recently, accumulating evidences indicate that miRNAs are extensively involved in cancer. However, it is a big challenge to identify which miRNAs are related to which cancer considering the complex processes involved in tumors, where one miRNA may target hundreds or even thousands of genes and one gene may regulate multiple miRNAs. Despite integrative analysis of matched gene and miRNA expression data can help identify cancer-associated miRNAs, such kind of data is not commonly available. On the other hand, there are huge amount of gene expression data that are publicly accessible. It will significantly improve the efficiency of characterizing miRNA's function in cancer if we can identify cancer miRNAs directly from gene expression data. We present a novel computational framework to identify the cancer-related miRNAs based solely on gene expression profiles without requiring neither miRNA expression data or the matched gene and miRNA expression data. The results on multiple cancer datasets show that our proposed method can effectively identify cancer related miRNAs with higher precision compared with other popular approaches. Furthermore, some of our novel predictions are validated by both differentially expressed miRNAs and evidences from literature, implying the predictive power of our proposed method. In addition, we construct a cancer-miRNA-pathway network, which can help explain how miRNAs are involved in cancer. Availability and implementation: The R code and data files for the proposed method are available at http://comp-sysbio.org/miR_Path/ © The Author (2014). Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
    Bioinformatics 12/2014; 31(8). DOI:10.1093/bioinformatics/btu811 · 4.62 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rational vaccine development can benefit from biomarker studies, which help to predict, optimize and evaluate the immunogenicity of vaccines and ultimately provide surrogate endpoints for vaccine trials. Systems biology approaches facilitate acquisition of both simple biomarkers and complex biosignatures. Yet, evaluation of high-throughput (HT) data requires a plethora of tools for data integration and analysis. In this review, we present an overview of methods towards evaluation and integration of large amounts of data collected in vaccine trials from similar and divergent molecular HT techniques, such as transcriptomic, proteomic and metabolic profiling. We will describe a selection of relevant statistical and bioinformatic approaches that are frequently associated with "systems biology." We will present data dimension reduction techniques, functional analysis approaches and methods of integrating heterogeneous HT data. Finally, we will provide a few examples of applications of these techniques in vaccine research and development. Copyright © 2015. Published by Elsevier Ltd.
    Vaccine 05/2015; DOI:10.1016/j.vaccine.2015.04.096 · 3.49 Impact Factor
  • Molecular Cancer Therapeutics 09/2014; DOI:10.1158/1535-7163.MCT-13-0876 · 6.11 Impact Factor